Study **I**^2 Odds Ratio (95% Crl) Afatinib Cetuximab vs Afatinib29 0.60 (0.30, 1.2) Pooled (pair-wise) 0.60 (0.14, 2.6) Indirect (back-calculated) NA 0.60 (0.14, 2.5) Pooled (network) **Chemotherapy vs Afatinib** 50 2.2 (1.0, 4.9) 2.2 (0.49, 10.) Pooled (pair-wise) Indirect (back-calculated) 8.7 (0.48, 1.6e+02) Pooled (network) 4.3% 3.0 (0.85, 13.) **Erlotinib** vs Afatinib 38 \rightarrow 9.9e+12 (1.1e-05, 8.5e+30) Pooled (pair-wise) → 1.2e+10 (1.7, 5.8e+33) Indirect (back-calculated) 0.80 (0.14, 4.7) Pooled (network) 51.0% 0.84 (0.14, 4.8) **Gefitinib** vs Afatinib 48 \rightarrow 1.2e+18 (4.2e-07, 3.4e+42) Pooled (pair-wise) \rightarrow 8.5e+10 (2.0, 6.6e+34) 0.99 (0.13, 7.3) Indirect (back-calculated) Pooled (network) 1.1 (0.14, 7.7) 52.3% Placebo vs Afatinib 54 \rightarrow 3.5e-23 (8.5e-57, 1.4e+11) 1.2e-13 (1.1e-31, 0.81) Pooled (pair-wise) 1.1 (0.14, 8.0) Indirect (back-calculated) Pooled (network) 41.9% 0.97 (0.12, 6.6) 0.01 80











